Inhibrx Biosciences vs Longeveron
Inhibrx Biosciences reported revenue of $1 million in fiscal 2025, about the same as Longeveron's $1 million in fiscal 2025. Inhibrx Biosciences' revenue grew 550.0% in its latest year, and Longeveron's fell 49.9%. Inhibrx Biosciences had an operating margin of -10386.5%, against -1942.2% at Longeveron. Free cash flow was −$130 million at Inhibrx Biosciences and −$19 million at Longeveron.
Side by side
| Inhibrx Biosciences | Longeveron | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1M | $1M |
| Revenue growth | 550.0% | −49.9% |
| Revenue growth a year, last 5 years | — | −26.5% |
| Gross margin | — | 67.0% |
| Operating margin | −10,386.5% | −1,942.2% |
| Net margin | −10,773.5% | −1,893.6% |
| Free cash flow | −$130M | −$19M |
| Free cash flow margin | −9,986.5% | −1,575.5% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 3.4% | 86.8% |
| Last close | $74.33 | $1.82 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | bought $5.5 million, sold $279,015 | — |
| Piotroski F-score | 2 of 8 | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Inhibrx BiosciencesLongeveron
Operating margin
Percent of revenue
Inhibrx BiosciencesLongeveron
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Inhibrx BiosciencesLongeveron
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Inhibrx Biosciences and Longeveron pages.